相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial
Sara Bringhen et al.
HAEMATOLOGICA (2020)
The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial
Charlotte Pawlyn et al.
LEUKEMIA (2020)
Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma
Meletios A. Dimopoulos et al.
BLOOD CANCER JOURNAL (2020)
Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma
Evangelos Terpos et al.
ANNALS OF HEMATOLOGY (2020)
Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial
Susanna J. Jacobus et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd
Ajai Chari et al.
EXPERT REVIEW OF HEMATOLOGY (2020)
Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)
Brian G. M. Durie et al.
BLOOD CANCER JOURNAL (2020)
Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance
Shaji K. Kumar et al.
LEUKEMIA (2019)
Retire statistical significance
Valentin Amrhein et al.
NATURE (2019)
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
T. Facon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Current status of autologous stem cell transplantation for multiple myeloma
Rama Al Hamed et al.
BLOOD CANCER JOURNAL (2019)
Navigating the treatment landscape in multiple myeloma: which combinations to use and when?
Hartmut Goldschmidt et al.
ANNALS OF HEMATOLOGY (2019)
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial
Meletios A. Dimopoulos et al.
LANCET (2019)
Managing multiple myeloma in elderly patients
Evan Diamond et al.
LEUKEMIA & LYMPHOMA (2018)
Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma
Paul G. Richardson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Front-line therapies for elderly patients with transplant-ineligible multiple myeloma and high-risk cytogenetics in the era of novel agents
Herve Avet-Loiseau et al.
LEUKEMIA (2018)
Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN)
Alessandra Larocca et al.
LEUKEMIA (2018)
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
M. -V. Mateos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Pathogenesis of bone disease in multiple myeloma: from bench to bedside
Evangelos Terpos et al.
BLOOD CANCER JOURNAL (2018)
Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting
Paul G. Richardson et al.
BLOOD CANCER JOURNAL (2018)
Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma
Thierry Facon et al.
BLOOD (2018)
Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients
Herve Avet-Loiseau et al.
BLOOD (2017)
Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma
Shaji Kumar et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
P. Moreau et al.
ANNALS OF ONCOLOGY (2017)
Impact of CRAB symptoms in survival of patients with symptomatic myeloma in novel agent era
Aya Nakaya et al.
HEMATOLOGY REPORTS (2017)
Bortezomib-containing regimens (BCR) for the treatment of non-transplant eligible multiple myeloma
Victor H. Jimenez-Zepeda et al.
ANNALS OF HEMATOLOGY (2017)
Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma
Meletios A. Dimopoulos et al.
HAEMATOLOGICA (2016)
Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma
Meletios A. Dimopoulos et al.
HAEMATOLOGICA (2016)
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
Pieter Sonneveld et al.
BLOOD (2016)
Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores
Monika Engelhardt et al.
HAEMATOLOGICA (2016)
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
Meletios A. Dimopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial
Cyrille Hulin et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
P. Moreau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores
Monika Engelhardt et al.
HAEMATOLOGICA (2016)
Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA
Maria Victoria Mateos et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report
Antonio Palumbo et al.
BLOOD (2015)
Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis
Neeraj Gupta et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
Lotfi Benboubker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
How should we treat newly diagnosed multiple myeloma patients?
Maria-Victoria Mateos et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2013)
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
S. Vincent Rajkumar et al.
BLOOD (2011)
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
Jesus F. San Miguel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
分享论文
